Abstract 6163
Background
Dexamethasone are often administered to prevent chemotherapy induced nausea and vomiting. The aim of this study was to assess the incidence of, and factors associated with, steroid induced metabolic syndrome in cancer patients receiving high emetic risk chemotherapy with antiemetic dexamethasone therapy.
Methods
This study was conducted retrospectively chart review of 356 patients who received high emetic risk chemotherapy with dexamethasone, aprepitant, and 5-HT3 antagonist between September 2015 and December 2017 at Chung-Ang University College of Medicine. Fasting plasma glucose levels. systolic blood pressure, diastolic blood pressure, triglyceride, HDL for the diagnosis of metabolic syndrome were performed before chemotherapy and 6 months after the start of chemotherapy.
Results
In total, 256 patients met the inclusion criteria and were included in analysis. The incidence of newly diagnosis metabolic syndrome was 17.5% (45 patients) after chemotherapy. The incidence of newly diagnosis diabetes and hypertension was 5.8% (15 patients), 26.2% (67 patients) after 6 months follow up. The mean metabolic syndrome score was 1.4 (range: 0-4) after chemotherapy. Multivariate analysis showed significant association of the incidence of streroid induced metabolic syndrome with BMI ≥ 25 (OR = 3.497, 95% CI = 1.064 – 11.494, p = 0.039) and colorectal cancer (OR = 0.088, 95% CI = 0.010-0.731, p = 0.024).
Conclusions
The incidence of steroid-induced metabolic syndrome after antiemetic dexamethasone therapy was high (17.4%). Therefore, we suggested that carefully measure glucose as well as LDL, triglyceride, blood pressure during antiemetic dexamethasone therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3309 - Heat Shock Protein 90 chaperones and Protein Kinase D3 regulates androgen-independent prostate cancer development
Presenter: Attila Varga
Session: Poster Display session 1
Resources:
Abstract
3441 - The SWI/SNF driven reprograming for the AR cistrome is NSD2 dependent
Presenter: Katia Ruggero
Session: Poster Display session 1
Resources:
Abstract
1659 - IGF1R inhibition affects the survival of HT29 cancer cells by alterations of the TLR9- and autophagy signaling
Presenter: Györgyi Műzes
Session: Poster Display session 1
Resources:
Abstract
1379 - Characterization of atypical dMMR (deficient MisMatch Repair) tumors: a study from a large cohort of 4948 cases
Presenter: Marion Jaffrelot
Session: Poster Display session 1
Resources:
Abstract
1657 - Modulation of TLR9-dependent autophagy response via inhibition of c-Met signaling influences the survival of HT29 cancer cells
Presenter: Ferenc Sipos
Session: Poster Display session 1
Resources:
Abstract
3045 - Positive Feedback Activation of Notch Signal by Obesity Enhances Colorectal Tumorigenicity
Presenter: Dake Chu
Session: Poster Display session 1
Resources:
Abstract
2285 - The Pathological and Functional Roles of BRPF1 in Hepatocellular Carcinoma
Presenter: Lai Hung Carol Cheng
Session: Poster Display session 1
Resources:
Abstract
3210 - Protein tyrosine phosphatase non-receptor type 3 (PTPN3) could be a new therapeutic target for pancreatic cancer.
Presenter: Akio Yamasaki
Session: Poster Display session 1
Resources:
Abstract
3920 - A Novel bispecific BCMAxCD3 T cell engaging antibody that treat multiple myeloma (MM) with minimal cytokine serection
Presenter: Zhenyu Li
Session: Poster Display session 1
Resources:
Abstract
2691 - Quantitative spatial profiling of lymphocyte-activation gene 3 (LAG-3)/major histocompatibility complex class II (MHC II) interaction in gastric and urothelial tumors
Presenter: Cyrus Hedvat
Session: Poster Display session 1
Resources:
Abstract